Safety evaluation of probiotic bifidobacteria by analysis of mucin degradation activity and translocation ability

Anaerobe

Volumn 16, Issue 2, 2010, Pages 131-136

  Abe, Fumiaki ^a   Muto, Masamichi ^a   Yaeshima, Tomoko ^a   Iwatsuki, Keiji ^a   Aihara, Hiroaki ^b   Ohashi, Yuji ^b   Fujisawa, Tomohiko ^b  

^a MORINAGA MILK INDUSTRY CO LTD   (Japan)

^b NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

Author keywords

Bifidobacteria; Bifidobacterium longum; Mucin; Safety; Translocation

Indexed keywords

AGAR; MUCIN; PROBIOTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ARTIFICIAL MILK; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL TRANSLOCATION; BIFIDOBACTERIUM; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; BLOOD; CARBON SOURCE; CECUM; COLON MUCOSA; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; ILEUM MUCOSA; IN VITRO STUDY; INTESTINE MUCOSA; KIDNEY; LIQUID CULTURE; LIVER; MALE; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; NUTRIENT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; SAFETY; SPLEEN;

ADULT; ANIMALS; BACTERIAL TRANSLOCATION; BIFIDOBACTERIUM; BLOOD; CARBON; FEMALE; HUMANS; INTESTINAL MUCOSA; KIDNEY; LIVER; LYMPH NODES; MALE; MICE; MICE, INBRED BALB C; MUCINS; PROBIOTICS; SPLEEN;

BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM BV. INFANTIS; MUS;

EID: 77951766386     PISSN: 10759964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2009.07.006     Document Type: Article

References (37)

1. Reddy B.S., Rivenson A. Inhibitory effect of Bifidobacterium longum on colon, mammary, and liver carcinogenesis induced by 2-amino-3-methylimidazo [4,5-f] quinoline, a food mutagen. Caser Research 1993, 53:3914-3918.
2. Ogata T., Nakamura T., Anjitsu K., Yaeshima T., Takahashi S., Fukuwatari T., et al. Effect of Bifidobacterium longum BB536 administration on the intestinal environment, defecation frequency and fecal characteristics of human volunteers. Bioscience and Microflora 1997, 16:53-58.
3. Yaeshima T., Takahashi S., Matsumoto N., Ishibashi N., Hayasawa H., Iino H. Effect of yogurt containing Bifidobacterium longum BB536 on the intestinal environment, fecal characteristics and defecation frequency: a comparison with standard yogurt. Bioscience and Microflora 1997, 16:73-77.
4. Namba K., Yaeshima T., Ishibashi N., Hayasawa H., Yamazaki S. Inhibitory effects of Bifidobacterium longum on enterohemorrhagic Escherichia coli O157:H7. Bioscience and Microflora 2003, 22:85-91.
5. Fujii T., Ohtsuka Y., Lee T., Kudo T., Shoji H., Sato H., et al. Bifidobacterium breve enhances transforming growth factor beta1 signaling by regulating Smad7 expression in preterm infants. Journal of Pediatric Gastroenterology and Nutrition 2006, 43:83-88.
6. Xiao J.Z., Kondo S., Yanagisawa N., Takahashi N., Odamaki T., Iwabuchi N., et al. Effect of probiotic Bifidobacterium longum BB536 in relieving clinical symptoms and modulating plasma cytokine levels of Japanese cedar pollinosis during the pollen season. A randomized double-blind, placebo-controlled trial. Journal of Investigational Allergology and Clinical Immunology 2006, 16:86-93.
7. Vinderola C.G., Prosello W., Ghiberto T.D., Reinheimer J.A. Viability of probiotic (Bifidobacterium, Lactobacillus acidophilus and Lactobacillus casei) and nonprobiotic microflora in Argentinian Fresco cheese. Journal of Dairy Science 2000, 83:1905-1911.
8. Mattila-Sandholm T., Myllärinen P., Crittenden R., Mogensen G., Fondén R., Saarela M. Technological challenges for future probiotic foods. International Dairy Journal 2002, 12:173-182.
9. Charalampopoulos D., Wang R., Pandiella S.S., Webb C. Application of cereals and cereal components in functional foods: a review. International Journal of Food Microbiology 2002, 15:131-141.
10. Champagne C.P., Gardner N.J., Roy D. Challenges in the addition of probiotic cultures to foods. Critical Reviews in Food Science and Nutrition 2005, 45:61-84.
11. Philips M., Kaliasapathy K., Tran L. Viability of commercial probiotic cultures (L. acidophilus, Bifidobacterium sp., L. casei, L. paracasei and L. rhamnosus) in cheddar cheese. International Journal of Food Microbiology 2006, 108:276-280.
12. Shortt C. The probiotic century: historical and current perspectives. Trends in Food Science and Technology 1999, 10:411-417.
13. Ishibashi N., Yamazaki S. Probiotic and safety. The American Journal of Clinical Nutrition 2001, 73:465S-470S.
14. Donohue D.C. Safety of probiotics. Asia Pacific Journal of Clinical Nutrition 2006, 15:563-569.
15. Snydman D.R. The safety of probiotics. Clinical Infectious Diseases 2008, 46:S104-S111.
16. Kunz A.N., Noel J.M., Firchok M.P. Two case of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. Journal of Pediatric Gastroenterology and Nutrition 2004, 38:457-458.
17. De Groote M.A., Frank N.D., Dowell E., Glode M.P., Pace N.R. Lactobacillus rhamonosus GG bacteremia associated with probiotic use in a child with short gut syndrome. The Pediatric Infectious Disease Journal 2005, 24:278-280.
18. Land M.H., Rouster-Stevens K., Woods C.H.R., Cannon M.L., Cnota J., Shetty A.K. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005, 115:178-181.
19. Gork A.S., Usui N., Ceriati E., Drongowski R.A., Epstein M.D., Coran A.G., et al. The effect of mucin on bacterial translocation in I-407fetal and Caco-2 adult enterocyte cultured cell lines. Pediatric Surgery International 1999, 15:155-159.
20. Zhou J.S., Gopal P.K., Gill H.S. Potential probiotic lactic acid bacteria Lactobacillus rhamnosus (HN001), Lactobacillus acidophilus (HN017) and Bifidobacterium lactis (HN019) do not degrade gastric mucin in vitro. International Journal of Food Microbiology 2001, 63:81-90.
21. Fernandez M.F., Boris S., Barbes C. Safety evaluation of Lactobacillus delbrueckii subsp. lactis UO 004, a probiotic bacterium. Research in Microbiology 2005, 156:154-160.
22. Puccio G., Cajozzo C., Meli F., Rochat F., Grathwohl D., Steenhout P. Clinical evaluation of a new starter formula for infants containing live Bifidobacterium longum BL999 and probiotics. Nutrition 2007, 23:1-8.
23. Chouraqui J.P., Grathwohl D., Labaune J.M., Hascoet J.M., de Montgolfirt I., Leclaire M., et al. Assessment of the safety, tolerance, and protective effect against diarrhea of infant formulas containing mixtures, of probiotics or probiotics and prebiotics in a randomized controlled trial. The American Journal of Clinical Nutrition 2008, 87:1365-1373.
24. Li Y., Shimizu T., Hosaka A., Kaneko N., Ohtsuka Y., Yamashiro Y. Effects of Bifidobacterium breve supplementation on intestinal flora of low birth weight infants. Pediatrics International 2004, 46:509-515.
25. Abe F., Muto M., Yaeshima T., Iwatsuki K. Effects of suspension-dilution buffers and plating media on enumeration of Bifidobacterium. Milchwissenchaft 2009, 64:139-142.
26. Kitahara M., Takamine F., Imamura T., Benno Y. Clostridium hiranonis sp. Nov., a human intestinal bacterium with bile acid 7α-dehydroxylating activity. International Journal of Systematic Bacteriology 2001, 39:224-229.
27. Mitsuoka T. Recent trends in research on intestinal flora. Bifidobacteria and Microflora 1982, 1:3-24.
28. Vankerchhoven V., Hys G., Vancanneyt M., Vael C., Klare I., Romond M.B., et al. Biosafety assessment of probiotics used for human consumption: recommendations from the EU-PROSAFE project. Trends in Food Science and Technology 2008, 19:102-114.
29. Liong M.T. Safety of probiotics: translocation and infection. Nutrition Reviews 2008, 66:192-202.
30. Ruas-Madiedo P., Gueimonde M., Fernadez-Garcia M., de los Reyes-Gavilan C.G., Margolles A. Mucin degradation by Bifidobacterium strains isolated from the human intestinal microbiota. Applied and Environmental Microbiology 2008, 74:1936-1940.
31. Yamazaki S., Machii K., Tsuyuki S., Momose H., Kawashima T., Ueda K. Immunological responses to monoassociated Bifidobacterium longum and their relation to prevention of bacterial invasion. Immunology 1985, 56:43-50.
32. Yamazaki S., Tsuyuki S., Tsuyuki S., Akashiba H., Kamimura H., Kimura M., et al. Immune response of Bifidobacterium-monoassociated mice. Bifidobacteria and Microflora 1991, 10:19-31.
33. Matsumoto T., Ishikawa H., Tateda K., Yaeshima T., Ishibashi N., Yamaguchi K. Oral administration of Bifidobacterium longum prevents gut-derived Pseudomonas aeruginosa sepsis in mice. Journal of Applied Microbiology 2008, 104:672-680.
34. Kabeir B.M., Yazid A.M., Stephenie W., Hakim M.N., Anas O.M., Shuhaimi M. Safety evaluation of Bifidobacterium pseudocatenulatum G4 as assessed in BALB/c mice. Letters in Applied Microbiology 2008, 46:32-37.
35. Zhou J.S., Shu Q., Rutherfurd K.J., Prasad J., Gopal P.K., Gill H.S. Acute oral toxicity and bacterial translocation studies on potentially probiotic strains of lactic acid bacteria. Food and Chemical Toxicology 2000, 38:153-161.
36. Lara-Villoslada F., Sierra S., Diaz-Repero M.P., Olivares M., Xaus J. Safety assessment of the human milk-isolated probiotic Lactobacillus salivarius CECT5713. Journal of Dairy Science 2007, 90:3583-3589.
37. Asahara T., Takahashi M., Nomoto K., Takayama H., Onoue M., Morotomi M., et al. Assessment of safety of Lactobacillus strains based on resistance to host innate defense mechanisms. Clinical and Diagnostic Laboratory Immunology 2003, 10:169-173.